



Global Supplier of Quality Peptide Products

Hemmo Pharmaceuticals Private Limited

Corporate Presentation



Corporate Overview



Company at a glance

- Commenced operations in 1966 as a trading house, focusing on Oxytocin amongst other products
- In 1979, ventured into manufacturing of Oxytocin
- Privately held family owned company
- Infrastructure
 - State of art manufacturing facility in Navi Mumbai,
 - R&D facilities at Thane and Spain
 - Corporate office at Worli

Key Highlights

Amongst the largest Indian peptide manufacturing company

Competent team of 154 people including 6 PhDs, 60+ chemistry graduates/post graduates and 3 engineers


Portfolio – Generic APIs, Custom Peptides for Research and Clinical Development and Peptide Fragments

Developed 21 generic products in-house.
5 more in progress

First and the only independent Indian company to have a US FDA approved peptide manufacturing site



Transition from a trading house to a research based manufacturing facility






Employee strength

Head count by department

Department	Head Count		
	Turbhe	Thane	Spain
Research & Development	-	8	6
Regulatory Affairs	2	-	-
Quality Assurance	10	-	-
Quality Control	46	5	-
Solution Phase Synthesis	21	-	-
Solution Phase Downstream	11	9	-
Solid Phase Synthesis	11	-	-
Solid Phase Downstream	17	-	-
Maintenance	15	3	-
Administration	10	3	-
Stores	8	-	-
PTL	3	-	-
Canteen	-	2	-
Total	154	30	6

Head count by qualification






Product Portfolio



Product Portfolio





Salient features

**India leadership
in most
peptides –
Globally
amongst top 5
Peptide
manufacturer**

**US DMF filed for
Oxytocin,
Desmopressin,
Leuprolide and
Octreotide**

**Cater to 3/4th
of the global
demand for
Oxytocin**

**~18%+ revenue growth
YTD**

**Key clients
include Pfizer,
Apotex, Merck
and Novartis**

**Hold CEP for
Oxytocin,
Desmopressin,
Somatostatin,
Leuprolide,
Calcitonin and
Buserelin**

**Leader in solution
phase Oxytocin ...
leading to large
quantities and
cost effective
processes**

**Strong export presence
accounting for ~75% of
revenues**

**Strong foothold in
pharmaceutical and vet
industries. Looking at
penetrating cosmetics and
innovator companies**

“Global Supplier of Quality Peptide Products”



Products under patents

Active	Brand	Application	Patented	Stage of Development
Eptifibatide	Intergrilin (Millenium)	Used in management of Percutaneous Coronary Intervention	Expired in 2015	Completed in Q3 2015
Glatiramer	Copaxone (Teva)	Used to treat Multiple Sclerosis	Expired in May 2015	Completed in Q2 2015
Atosiban	Tractocile (Ferring)	Used as Tocolytic to halt premature labour	Expired in 2008	Completed in Q2 2015
Exenatide	Byetta (Amylin)	Used in treatment of Type 2 Diabetes	Yes Patent to expire in Dec 2016	To be completed in Q2 2016
Glucagon	Glucagen (Novo Nordisk)	Used in treatment of Hyperglycemia	Expired in July 2014	To be completed in Q2 2016
Degarelix	Firmagon (Ferring)	Used in treatment of Prostate Cancer	Yes Patent to expire in 2020	Completed in Q4 2015



Infrastructure Overview




Infrastructure overview

Site	Distance from airport	Activity	Owned / rented	Commenced in	Built up area (sq. ft.)	Head count
Turbhe, Navi Mumbai	30 km	Manufacturing all products including Oxytocin for regulated markets	Owned	2007	50,000 (Additional 25,000 Sq. ft. can be constructed)	154
Thane	30 km	R&D centre and manufacturing of Oxytocin for non regulated markets	Owned	1986	10,000	30
Girona, Spain	N/A	R&D center	Rented	2012	2,000	6
Mahalaxmi, Mumbai	17 km	Corporate office	Owned	2003	2,700	16




Strong in-house QC capabilities





Quality Assurance team






Business Development Initiatives



Sales Reach – Direct and Distributors



Focus geographies are USA, Canada, Europe, Asian Subcontinent and Latin America which contribute to majority of exports

End of Presentation